SCHEMBL4568192

SCHEMBL4568192

COC(=O)c1cccc(Cc2c(-c3cccc(OC)c3)[nH]c3cc(OC)ccc23)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
USP2 O75604 1/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MTNR1A P48039 3/20 0.41
MTNR1B P49286 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SERPINE1 P05121 1/20 0.41
CHRM4 P08173 1/20 0.41
DRD2 P14416 1/20 0.41
HTR7 P34969 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3706006 0.94 MTNR1A (0.48) KDM4EALDH1A1HPGDHSD17B10MTNR1A
SCHEMBL4568175 0.93 PTGS2 (0.42) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL4568186 0.93 MAPK13 (0.51) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL4568427 0.93 TUBB4A (0.46) ALOX15MAPK13MAPK12MAPK11MAPK14
SCHEMBL4568432 0.93 PLA2G2A (0.40) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL3704461 0.91 GPR17 (0.44) KDM4EALDH1A1HPGDHSD17B10MTNR1A
SCHEMBL4568426 0.91 KDM4E (0.45) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL4568435 0.91 MTNR1A (0.41) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL4568176 0.90 MDM4 (0.41) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL4568421 0.90 KDM4E (0.46) KDM4EMAPTALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R KDM4E 3521/4885MAPT 3199/4885ALDH1A1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.